These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20185350)

  • 1. [Effectiveness and safety of 5-azacitidine in three patients with myelodysplastic syndromes].
    Garzás-Martín de Almagro MC; Gago Sánchez AI; Cuevas Asencio I; Reyes Malia M
    Farm Hosp; 2010; 34(4):204-8. PubMed ID: 20185350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
    Breccia M; Finsinger P; Loglisci G; Federico V; Santopietro M; Colafigli G; Petrucci L; Salaroli A; Serrao A; Latagliata R; Alimena G
    Ann Hematol; 2012 Sep; 91(9):1345-9. PubMed ID: 22569854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effective treatment of myelodysplastic syndromes-refractory anemia with excess blasts type II by decitabine: a case report].
    Bao L; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):573. PubMed ID: 22967422
    [No Abstract]   [Full Text] [Related]  

  • 4. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
    Musto P; Maurillo L; Spagnoli A; Gozzini A; Rivellini F; Lunghi M; Villani O; Aloe-Spiriti MA; Venditti A; Santini V;
    Cancer; 2010 Mar; 116(6):1485-94. PubMed ID: 20151429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia.
    Bernal T; Moncada-Pazos A; Soria-Valles C; Gutiérrez-Fernández A
    Exp Hematol; 2013 Feb; 41(2):172-9. PubMed ID: 23085464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
    Lee YG; Kim I; Yoon SS; Park S; Cheong JW; Min YH; Lee JO; Bang SM; Yi HG; Kim CS; Park Y; Kim BS; Mun YC; Seong CM; Park J; Lee JH; Kim SY; Lee HG; Kim YK; Kim HJ;
    Br J Haematol; 2013 May; 161(3):339-47. PubMed ID: 23432512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes.
    Musto P; Falcone A; Sanpaolo G; Bisceglia M; Matera R; Carella AM
    Haematologica; 2002 Aug; 87(8):884-6. PubMed ID: 12161367
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.
    Itzykson R; Thépot S; Eclache V; Quesnel B; Dreyfus F; Beyne-Rauzy O; Turlure P; Vey N; Recher C; Boehrer S; Gardin C; Adès L; Fenaux P;
    Leukemia; 2011 Jul; 25(7):1207-9. PubMed ID: 21468040
    [No Abstract]   [Full Text] [Related]  

  • 11. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.
    Sekeres MA; O'Keefe C; List AF; Paulic K; Afable M; Englehaupt R; Maciejewski JP
    Am J Hematol; 2011 Jan; 86(1):102-3. PubMed ID: 21080340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
    Salim O; Toptas T; Avsar E; Yucel OK; Ozturk E; Ferhanoglu B; Geduk A; Mehtap O; Tombak A; Tiftik EN; Deveci B; Kurtoglu E; Kara O; Atagunduz IK; Tuglular TF; Undar L
    Leuk Res; 2016 Jun; 45():82-9. PubMed ID: 27107658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 14. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
    Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
    J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
    Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
    J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
    Breccia M; Loglisci G; Salaroli A; Serrao A; Petrucci L; Mancini M; Alimena G
    Leuk Lymphoma; 2012 Aug; 53(8):1558-60. PubMed ID: 22280532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
    Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
    Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
    Fenaux P; Ades L
    Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan].
    Tomonaga M; Kamae I
    Rinsho Ketsueki; 2012 Mar; 53(3):310-7. PubMed ID: 22499047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azacitidine: a new medication associated with Sweet syndrome.
    Tintle S; Patel V; Ruskin A; Halasz C
    J Am Acad Dermatol; 2011 May; 64(5):e77-9. PubMed ID: 21496689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.